Overview

Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This multiple ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of PRX002 in approximately 60 patients with Parkinson's disease.
Phase:
Phase 1
Details
Lead Sponsor:
Prothena Biosciences Limited
Collaborator:
Hoffmann-La Roche